Inbio Ventures
VC
2013
$300 M
Russia
Investment Ticket
Investment Horizon
Investment Stage
Exit Strategy
Profile
Over $200m deployed in early stage biotech companies through investments and strategic deals. 360˚ knowledge of the sector.
Evolution stages: Academia, In-house Industrial R&D, Corporate VC and Business Development, Professional Regulated Public Equities Asset Management.
Top positions in venture and production biotech companies in USA, Russia, Canada, EU: Pharmstandard, Generium, Aquinox, Protagonist, Codon, Allena, Transmedics and others
Inbio ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally.
Therapeutic areas of the highest priority are the following:
-Oncology
-Inflammation
-Autoimmune diseases
-Orphan genetic diseases
-Critical care
-Cell-based therapy and regenerative medicine
-Stage of development
The project, ideally, should at least have passed the in-vivo proof-of-concept (PoC), and should have a strong scientific background behind it. Management team with appropriate experience is a substantial advantage.
